User:Erculsyn/Sample page

Welcome to Wikipedia! This page is a sandbox, an area where you can experiment and test edits. It contains simple examples of various elements you'll find around Wikipedia. It may be deleted after a period of inactivity; please do not use it to draft an article or create anything else you wish to last.

This is a section heading


Here is a citation to a website.

Here is a citation to a news article.

Here is a template for facts that lack a citation.

Here is a link to the page for Wikipedia founder Jimmy Wales. The text displayed for the link can be customized like this. When links go to pages that do not exist, they appear red, like this.

This is a subsection heading

 * Bulleted list item 1
 * Bulleted list item 2

You can make text bold or italic when needed.


 * 1) Numbered list item 1
 * 2) Numbered list item 2

About
Peter Karl Sorger (born February 13, 1961 in Halifax Nova Scotia, Canada) is a systems and cancer biologist and Otto Krayer Professor of Systems Pharmacology in the Department of Systems Biology at Harvard Medical School. Sorger is the founding head of the Harvard Program in Therapeutic Science (HiTS), Director of its Laboratory of Systems Pharmacology (LSP), and Co-Director of the Harvard MIT Center for Regulatory Science. He was previously a Professor of Biology and Biological Engineering at the Massachusetts Institute of Technology where he co-founded its program on Computational and Systems Biology (CSBi). Sorger is known for his work in the field of systems biology and for having helped launch the field of computational and systems pharmacology. His research focuses on the molecular origins of cancer and approaches to accelerate the development of new medicines. Sorger teaches Principles and Practice of Drug Development at Massachusetts Institute of Technology and Harvard University.

Early Life
Sorger was born on February 13, 1961 in Halifax Nova Scotia, Canada to Scottish and Austrian parents. His family immigrated to the US in 1963. He graduated summa cum laude from Harvard College in 1983 (in Biochemistry) where he studied the assembly of icosahedral viruses under the supervision of Stephen C. Harrison. He received his PhD for Biochemistry as a Marshall Scholar from Trinity College, Cambridge for research on the transcriptional regulation of heat shock genes, under the supervision of Hugh Pelham at the Medical Research Council Lab in Cambridge, England. He then trained as a Richard Childs Fellow and Lucille P Markey Scholar with Harold Varmus and Andrew Murray at the University of California, San Francisco. Sorger joined the MIT Department of Biology in 1984 following a year as a Visiting Scientist with Anthony A. Hyman at the European Molecular Biology Laboratory, Heidelberg, Germany. Sorger became a full Professor in the MIT Biology and Biological Engineering Departments in 2004.

Sorger’s postdoctoral and early faculty research led to the first reconstitution of a chromosome-microtubule attachment (a yeast kinetochore) and the subsequent identification of multiple kinetochore proteins3,4. His group identified mammalian homologs of the checkpoint proteins that regulate entry into mitosis, and showed that mutations in these genes can be oncogenic because they cause chromosome instability5–7. This work contributed substantially to our understanding of the faithful transmission of chromosomes from mother to daughter cells. Defects in these mechanisms cause aneuploidy that plays a major role in oncogenic transformation.

Career
Working closely with Doug Lauffenburger and funded by the Defense Advanced Research Projects Agency and the National Institutes of Health’s National Centers for Systems Biology program REF, Sorger’s work in the 1990s increasingly focused on oncogenesis itself and on mammalian signal transduction8. Sorger and Lauffenburger’s approach combined molecular genetics, live-cell microscopy and mechanistic computational modeling.9,10 Their focus on biochemistry REF was unusual in an era dominated by genomics and ultimately led Sorger to co-found the software company Glencoe Software and the biotech company Merrimack Pharmaceuticals. Subsequent work by Sorger’ group led to a new understanding of stochastic fluctuation in cellular responses to natural ligands and drugs11,12 and to the development of a range of innovative computational methods, including the biochemistry-specific Python (programming language) PySB13 and the natural language processing and knowledge assembly system INDRA14 REF.

In 2011, Sorger oversaw the preparation of a widely cited White Paper for the NIH entitled Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms. This white paper envisioned the emergence of an empirically-based but computationally sophisticated approach to the science underlying development of innovative new medicines. Sorger move to Harvard Medical School REF to pursue these approaches by establishing the Laboratory of Systems Pharmacology, which merges laboratory experiments, computer science, and medicine to fundamentally improve drug discovery REF. Funding from the Massachusettes Life Sciences Center in 2014 and 2017 Ref2 made the lab a reality and it now has 150 faculty trainees and staff from ten Boston-area institutions including Harvard University, MIT, Tufts University, Northeastern University and five Harvard-affiliated Hospitals.

Sorger’s systems pharmacology research involves three approaches centered on cancer. The first focuses on preclinical pharmacology, the stage at which the molecular mechanisms of disease are studied and new drugs sought. An extensive investigation into the causes of irreproducibility drug-response measurements15 led to a series of conceptual16, computational17, and experimental improvements18 in scoring drug action that are now widely used in academe and industry and have enabled the discovery of new mechanisms of action for existing drugs19. Recent work has focused on deep learning as means to further understand complex protein networks and drug mechanisms20,21. The second project involves developing methods to study drug mechanism at scale in patients through highly multiplexed tissue imaging22,23 of the biopsies routinely acquired from patients (particularly cancer patients) REF. This has led to a very rapidly growing tissue imaging and digital histology program that is part of the US National Cancer Institute Moonshot and promises to substantially advance precision cancer care.24 The third project involves studying the clinical trial record to understand how successful and failed trials differ. An early success was the discovery that the great majority of approved combination cancer therapies exhibit independent action – not synergy25,26. As Merck investigators subsequently realized, this fundamentally changes how immunotherapy combinations should be developed27. The group is now engaged in a large-scale effort REF to digitize and make freely available all survival data from Phase 3 trials.28

COVID-19 Pandemic Research
One of the enduring images of the early phase of the COVID-19 pandemic was of healthcare workers with inadequate face masks, respirators and other personal protective equipment. To address this issue, Sorger, physician Nichol Leboeuf and MD-PhD student Deborah Plana established the Boston Area Pandemic Fabrication team (PanFab). This team of students and alumni from MIT and Harvard teamed up with local industry and led a series of 3D printing and rapid-turn manufacturing projects to make face shields30, mask frames31, powered air purifying respirators32 and new ways to sterilize and reuse 95 respirators33. PanFab led to over a dozen open access publications and designs, including a thorough review of lessons learned34 and a hope that we can be better prepared for future pandemics.

External links section
Example external link